- Title: Subtitle
- 1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE
- Creators
- A. Nizam - Cleveland ClinicL. Zhang - University of California, San FranciscoC.Y. Jiang - The University of Texas MD Anderson Cancer CenterC.B. Nguyen - University of Michigan–Ann ArborD.R. Bakaloudi - Fred Hutch Cancer CenterM.A. Bilen - Winship Cancer InstituteP.M. Coelho Barata - University Hospitals Seidman Cancer CenterY. Zakharia - University of IowaM.I. Milowsky - University of North Carolina at Chapel HillD. Kilari - Medical College of WisconsinC.J. Hoimes - Duke Cancer InstituteA.R. Khaki - Stanford UniversityH. Emamekhoo - University of Wisconsin Carbone Cancer CenterS. Gupta - Cleveland ClinicP. GrivasJ. Bellmunt - Dana-Farber Cancer InstituteA.S. Alva - University of Michigan–Ann ArborM.T. Campbell - The University of Texas MD Anderson Cancer CenterO. Alhalabi - The University of Texas MD Anderson Cancer CenterV.S. Koshkin - UCSF Helen Diller Family Comprehensive Cancer Center
- Resource Type
- Abstract
- Publication Details
- Annals of oncology, Vol.35(Supplement 2), pp.S1142-S1142
- Publisher
- Elsevier Ltd
- DOI
- 10.1016/j.annonc.2024.08.2057
- ISSN
- 0923-7534
- Language
- English
- Date published
- 09/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984708762402771
Abstract
1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE
Annals of oncology, Vol.35(Supplement 2), pp.S1142-S1142
09/2024
DOI: 10.1016/j.annonc.2024.08.2057
Details
Metrics
1 Record Views